AKT1 and colorectal carcinoma: Through a series of systematic experiments, it could be revealed that DDX49 contributes to CRC progression via the TIMM44-PI3K-AKT pathway, thereby providing novel experimental evidence for prognostic assessment and therapeutic target development in CRC.